Jounce Therapeutics Inc. (JNCE) reported disappointing preliminary results from its ongoing Phase 1/2 trial of JTX-2011 alone and in combination with nivolumab in patients with advanced solid tumors Monday morning.
from RTT - Before the Bell https://ift.tt/2LZ7Qap
via IFTTT
No comments:
Post a Comment